Get started
Markets US Stocks Health Technology Biotechnology

Atreca, Inc

BCEL NASDAQ
BCEL
Atreca, Inc NASDAQ
See more on advanced chartSee more on advanced chart
 
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
See more on advanced chartSee more on advanced chart
Overview
Ideas Financials Technicals

BCEL Stock Chart

Ideas

Videos only
$BCEL ALL TIME LOW
BCEL
, D
Long
BCEL: $BCEL ALL TIME LOW

Recently BCEL has reached an all time low and a data suggests that is will rise back up. According to Fintel.IO Blackrock has bought a staggering 350k shares. The rating of the stock has changed to hold according to some analysts. It's at an all time low, buy folks thanks me later.

Atreca Inc - It's time to load up. 🧙
BCEL
, 1D
Long
BCEL: Atreca Inc - It's time to load up. 🧙

Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target-derived from an antibody identified using...

If good for Bill Gates good for us 🧙
BCEL
, 1D
Long
BCEL: If good for Bill Gates good for us 🧙

Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target-derived from an antibody identified using...

Hull Moving
BCEL
, 60
Long
BCEL: Hull Moving

Hull Moving Averages ( x3) all turned up going to run up for awhile with some dips. in at $13.08 x 400

ATRECA
BCEL
, 1D
Long
BCEL: ATRECA

price drop after public offering at $16 in future stock should test $24

BCEL - Make or break moment; 40% potential UP or DOWN
BCEL
, 1D
BCEL: BCEL - Make or break moment; 40% potential UP or DOWN

Atreca has come down to rising channel support. There's also the 100 ema involved, which has many times acted as watershed support\resistance (YELLOW arrows). If this channel and moving average hold, BCEL could quickly go back to all-time highs for a 44% gain. If channel breaks to the downside, March lows are 40% away. I would absolutely wait for solid...

collab with XNCR announced
BCEL
, 60
Long
BCEL: collab with XNCR announced

Please leave a like and follow for more

BCEL review
BCEL
, 1D
BCEL: BCEL review

This is a review of my previous chart setup. Over 18%! I’m rich now lol. My best chart setup so far. Glad some of you guys could have made money on this one. If you want to hold this stock that’s completely ok but I am going to sell tomorrow.

BCEL
BCEL
, 1D
Long
BCEL: BCEL

Closed over support with super high volume! Is the bearish trend over?

Technicals

Financials

Valuation
Enterprise Value/EBITDA, TTM —
Enterprise Value, FQ —
Market Cap — Basic —
Number of Employees —
Number of Shareholders —
Price/Earnings, TTM —
Price/Revenue, TTM —
Price/Book Ratio, FY —
Price/Sales Ratio, FY —
Balance Sheet
Current Ratio, FQ —
Debt to Equity, FQ —
Net Debt, FQ —
Quick Ratio, FQ —
Total Assets, FQ —
Total Debt, FQ —
Operating Metrics
Return on Assets, TTM —
Return on Equity, TTM —
Return on Invested Capital, TTM —
Revenue per Employee, TTM —
Price History
Average Volume (10 day) —
Beta - 1 Year —
Price - 52 Week High —
Price - 52 Week Low —
Dividends
Dividends Paid, FY —
Dividends per Share, FY —
Expected Annual Dividends —
Dividends Yield —
Margins
Net Margin, TTM —
Gross Margin, TTM —
Operating Margin, TTM —
Pretax Margin, TTM —
Income Statement
Basic EPS, Net Income —
Earnings per Share, Basic, TTM —
EBITDA, TTM —
Gross Profit, FY —
Last Annual EPS —
Last Annual Revenue, FY —
Net Income, FY —
Total Revenue, FY —
Free Cash Flow, TTM —
More financials

Profile

Sector: Health Technology
Industry: Biotechnology
Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman on June 11, 2010 and is headquartered in San Carlos, CA.

Breaking news